Sigumir — EU research guide.
Sigumir is a synthetic tetrapeptide (Val-Glu-Pro-Asp) from the Khavinson bioregulator series targeting cartilage and joint tissue, proposed to regulate chondrocyte gene expression. It is studied in the same general category as Cartalax, another connective-tissue bioregulator in the same family.
What is Sigumir?
Sigumir is a synthetic tetrapeptide (Val-Glu-Pro-Asp) from the Khavinson bioregulator series targeting cartilage and joint tissue, proposed to regulate chondrocyte gene expression. It is studied in the same general category as Cartalax, another connective-tissue bioregulator in the same family.
What does the research show?
Published research is limited to small animal models of age-related cartilage degeneration. No independently replicated human trial data is publicly available as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. Available from a small number of specialist research vendors for laboratory use only.
Molecular information
Pharmacokinetics
Sigumir is not yet in our price comparison
We expand EU supplier coverage every month.